BACKGROUND: The observed association between Depo-Provera injectable use and increased HIV acquisition may be caused by hormone-induced increased susceptibility to other sexually transmitted infections (STIs) or changes in the cervicovaginal microbiota (VMB), accompanied by genital immune activation and/or mucosal remodeling. METHODS: Rwandan female sex workers (n = 800) were interviewed about contraceptive use and sexual behavior and were tested for STIs, bacterial vaginosis by Nugent score and pregnancy, at baseline. A subset of 397 HIV-negative, nonpregnant women were interviewed and tested again at regular intervals for 2 years. The VMB of a subset of 174 women was characterized by phylogenetic microarray. Outcomes of STI and VMB were compared between women with hormonal exposures (reporting oral contraceptive or injectable use, or testing positive for pregnancy) and controls (not reporting hormonal contraception and not pregnant). RESULTS: Oral contraceptive use was associated with increased human papillomavirus prevalence (adjusted odds ratio [aOR], 3.10; 1.21-7.94) and Chlamydia trachomatis incidence (aOR, 6.13; 1.58-23.80), injectable use with increased herpes simplex virus-2 prevalence (aOR, 2.13; 1.26-3.59) and pregnancy with lower HIV prevalence (aOR, 0.45; 0.22-0.92) but higher candidiasis incidence (aOR, 2.14; 1.12-4.09). Hormonal status was not associated with Nugent score category or phylogenetic VMB clustering, but oral contraceptive users had lower semiquantitative vaginal abundance of Prevotella, Sneathia/Leptotrichia amnionii, and Mycoplasma species. CONCLUSIONS: Oral contraceptive and injectable use were associated with several STIs but not with VMB composition. The increased herpes simplex virus-2 prevalence among injectable users might explain the potentially higher HIV risk in these women, but more research is needed to confirm these results and elucidate biological mechanisms.
BACKGROUND: The observed association between Depo-Provera injectable use and increased HIV acquisition may be caused by hormone-induced increased susceptibility to other sexually transmitted infections (STIs) or changes in the cervicovaginal microbiota (VMB), accompanied by genital immune activation and/or mucosal remodeling. METHODS: Rwandan female sex workers (n = 800) were interviewed about contraceptive use and sexual behavior and were tested for STIs, bacterial vaginosis by Nugent score and pregnancy, at baseline. A subset of 397 HIV-negative, nonpregnant women were interviewed and tested again at regular intervals for 2 years. The VMB of a subset of 174 women was characterized by phylogenetic microarray. Outcomes of STI and VMB were compared between women with hormonal exposures (reporting oral contraceptive or injectable use, or testing positive for pregnancy) and controls (not reporting hormonal contraception and not pregnant). RESULTS: Oral contraceptive use was associated with increased human papillomavirus prevalence (adjusted odds ratio [aOR], 3.10; 1.21-7.94) and Chlamydia trachomatis incidence (aOR, 6.13; 1.58-23.80), injectable use with increased herpes simplex virus-2 prevalence (aOR, 2.13; 1.26-3.59) and pregnancy with lower HIV prevalence (aOR, 0.45; 0.22-0.92) but higher candidiasis incidence (aOR, 2.14; 1.12-4.09). Hormonal status was not associated with Nugent score category or phylogenetic VMB clustering, but oral contraceptive users had lower semiquantitative vaginal abundance of Prevotella, Sneathia/Leptotrichia amnionii, and Mycoplasma species. CONCLUSIONS: Oral contraceptive and injectable use were associated with several STIs but not with VMB composition. The increased herpes simplex virus-2 prevalence among injectable users might explain the potentially higher HIV risk in these women, but more research is needed to confirm these results and elucidate biological mechanisms.
Authors: J Paul Brooks; David J Edwards; Diana L Blithe; Jennifer M Fettweis; Myrna G Serrano; Nihar U Sheth; Jerome F Strauss; Gregory A Buck; Kimberly K Jefferson Journal: Contraception Date: 2016-11-29 Impact factor: 3.375
Authors: Kristin D Gerson; Clare McCarthy; Michal A Elovitz; Jacques Ravel; Mary D Sammel; Heather H Burris Journal: Am J Obstet Gynecol Date: 2019-12-06 Impact factor: 8.661
Authors: Kristin D Gerson; Clare Mccarthy; Jacques Ravel; Michal A Elovitz; Heather H Burris Journal: Am J Perinatol Date: 2020-10-08 Impact factor: 1.862
Authors: Hanneke Borgdorff; Stuart D Armstrong; Hanne L P Tytgat; Dong Xia; Gilles F Ndayisaba; Jonathan M Wastling; Janneke H H M van de Wijgert Journal: PLoS One Date: 2016-03-10 Impact factor: 3.240
Authors: Lindsay M Kindinger; Phillip R Bennett; Yun S Lee; Julian R Marchesi; Ann Smith; Stefano Cacciatore; Elaine Holmes; Jeremy K Nicholson; T G Teoh; David A MacIntyre Journal: Microbiome Date: 2017-01-19 Impact factor: 14.650
Authors: Deborah Bartz; Rie Maurer; Jessica Kremen; Jennifer M Fortin; Elizabeth Janiak; Alisa B Goldberg Journal: Contracept Reprod Med Date: 2017-01-07
Authors: Chelsea B Polis; Kathryn M Curtis; Philip C Hannaford; Sharon J Phillips; Tsungai Chipato; James N Kiarie; Daniel J Westreich; Petrus S Steyn Journal: AIDS Date: 2016-11-13 Impact factor: 4.177